¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Abnormality of plasma protein, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
  • protein granule
    ´Ü¹éÁú°ú¸³
  • protein kinase
    ´Ü¹éÁúŰ³ª¾ÆÁ¦
  • protein kinase C
    ´Ü¹éÁúŰ³ª¾ÆÁ¦C
  • protein layer
    ´Ü¹éÁúÃþ
  • protein p53
    ´Ü¹éÁúp53
  • protein quotient
    ´Ü¹éÁúÁö¼ö
  • protein S
    ´Ü¹éÁúS
  • protein score
    ´Ü¹éÁú°¡
  • protein sensitization
    ´Ü¹éÁú¹Î°¨È­
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ
  • protein-losing enteropathy
    ´Ü¹éÁú¼Ò½ÇÀ庴(Áõ)
  • purified protein derivative
    Á¤Á¦´Ü¹éÁúÀ¯µµÃ¼
  • reserve protein
    ÀúÀå´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • prosthetic protein
    ¹èÇմܹé
  • protein quotient
    ´Ü¹éÁö¼ö
  • protein score
    ´Ü¹é°¡
  • protein sensitization
    ´Ü¹é¹Î°¨
  • reserve protein
    ÀúÀå´Ü¹éÁú
  • specific protein
    ƯÀ̴ܹéÁú
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
  • stress protein
    ½ºÆ®·¹½º´Ü¹éÁú
  • structural protein
    ±¸Á¶´Ü¹é, ±¸Á¶´Ü¹éÁú
  • vehicle protein
    ¿î¹Ý´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ(Ó±ÛÜùêà÷ì×í­).
  • protein therapy
    ´Ü¹é(Áú)¿ä¹ý(¡­èþÛö).
  • protein,actin-binding
    ¾×ƾ-°áÇÕ(´Ü¹é)
  • protein,al
    AL(´Ü¹é)
  • protein,bence jones
    º¥½º-Á¸½º(´Ü¹é)
  • protein-calorie deficiency
    ´Ü¹é(Áú)¿­·®°áÇÌ(Ó±ÛÜ(òõ)æðÕáÌÀù¹)
  • protein-calorie malnutrition
    ´Ü¹é(Áú)¿­·®¿µ¾ç½ÇÁ¶(Áõ)(Ó±ÛÜ(òõ)æðÕáç½å×ã÷ðà(ñø))
  • protein-energy malnutrition
    ´Ü¹é(Áú)¿¡³ÊÁö¿µ¾ç½ÇÁ¶(Áõ)(¡­ç½å×ã÷ðà(ñø))
  • protein-losing
    ´Ü¹é»ó½Ç¼º.
  • protein-losing enteropathy
    ´Ü¹é»ó½Ç¼º À庴Áõ(íóÜ»ñø)
  • protein-losing enteropathy
    ´Ü¹é»ó½ÇÀ庴Áõ(Ó±ÛÜßÃã÷íóÜ»ñø)
  • racemized protein
    ¶ó¼¼¹ÌÈ­´Ü¹éÁú(¡­ûùÓ±ÛÜòõ).
  • ras protein
    ras ´Ü¹é(¡­Ó±ÛÜ)
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ(¡­ì×í­)
  • plasma globulin
    ÇöóÁ±Û·ÎºÒ¸°, Ç÷Àå±Û·ÎºÒ¸°.
  • plasma hemoglobin
    Ç÷ÀåÇì¸ð±Û·Îºó, Ç÷ÀåÇ÷¾×¼Ò.
  • plasma histaminase activity
    Ç÷ÀåÈ÷½ºÅ¸¹Ì³ª¾ÆÁ¦È°¼ºµµ.
  • plasma hydrolysate
    Ç÷Àå°¡¼öºÐÇØ¹°(¡­Ê¥â©ÝÂú°Úª).
  • plasma iron
    Ç÷Àåö(úìíìôÑ).
  • plasma iron disappearance
    Ç÷Àåö¼Ò½Ç(úìíìôÑá¼ã÷).
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü(úìíìôÑá¼ã÷ëÒ).
  • plasma iron pool
    Ç÷ÀåöÀúÀå°í.
  • plasma iron turnover
    Ç÷Àåö±³Ã¼
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À².
  • plasma lipoprotein abnormalities
    Ç÷ÀåÁöÁú´Ü¹éÁúÀÌ»óÁõ.
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ¿øÇüÁú¸·
  • plasma membrane
    ÇüÁú¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • early protein
    Á¶±â ´Ü¹éÁú (ðÄÑ¢Ó±ÛÜòõ)
  • ectopic protein
    ÀÌ¼Ò ´Ü¹éÁú(ì¶á¶Ó±ÛÜòõ)
  • eIF-2 stimulating protein
    eIF-2 ÀÚ±Ø ´Ü¹éÁú(í©Ð½Ó±ÛÜòõ)
  • electron transfer protein
    ÀüÀÚÀü´Þ ´Ü¹éÁú(ï³í­îîÓ¹Ó±ÛÜòõ)
  • encephalitogenic protein
    ³ú¿°»ý¼º ´Ü¹éÁú(Òàæúßæà÷Ó±ÛÜòõ)
  • exocellular protein
    ¼¼Æ÷(á¬øà)¹Û ´Ü¹éÁú(Ó±ÛÜòõ)
  • expressor protein
    ¹ßÇöÀÚ ´Ü¹éÁú (Û¡úÞí­Ó±ÛÜòõ)
  • fast protein liquid chromatography
    °í¼Ó ´Ü¹éÁú ¾×ü(ÍÔáÜÓ±ÛÜòõäûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • FeMo protein
    FeMo ´Ü¹éÁú(Ó±ÛÜòõ)
  • Fe protein
    Fe ´Ü¹éÁú (Ó±ÛÜòõ)
  • Fe-S protein
    Fe-S ´Ü¹éÁú (Ó±ÛÜòõ)
  • fibrous protein
    ¼¶À¯»ó ´Ü¹éÁú (àéë«ßÒÓ±ÛÜòõ)
  • fused protein
    À¶ÇÕ ´Ü¹éÁú(ë×ùêÓ±ÛÜòõ)
  • gelation protein
    Á©Çü¼º(û¡à÷) ´Ü¹éÁú(Ó±ÛÜòõ)
  • globular protein
    ±¸»ó(ϹßÒ) ´Ü¹éÁú(Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
EA early antigen; educational age; egg albumin; electric affinity; electrical activity; electroacupunct...
MAKA major karyotypic abnormality
NEA neoplasm embryonic antigen; no evidence of abnormality
NHA National Health Association; National Hearing Association; National Hemophilia Association; nonspeci...
NSA Neurological Society of America; normal serum albumin; no salt added; no significant abnormality; no...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
LPM Liver plasma membranes
L/P Lymph/plasma
PPF Papillary plasma flow
P Plasma
PV Plasma
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
two-component plasma <radiobiology> Refers to a plasma containing a cool thermal component and a population of high energy particles (such as from neutral beam injection) which are in the process of thermalising (slowing down).
(09 Oct 1997)
kern-plasma relation theory A theory enunciated by Hertwig (1903) that a definite relation as to size normally exists in every cell between the mass of nuclear material and that of the protoplasm.
Origin: Ger. Kern, kernel, nucleus
(05 Mar 2000)
fresh frozen plasma The fluid component of blood lacking the cells but containing all the necessary plasma proteins, used to restore the protein clotting factors in some individuals with clotting factor deficiencies.
(27 Sep 1997)
acetoacetyl-acyl carrier protein synthase <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin
Registry number: EC 2.3.1.-
Synonym: acetoacetyl-acp synthase
(26 Jun 1999)
acid soluble spore protein <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light.
(18 Nov 1997)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acyl-(acyl-carrier-protein)-phospholipid acyltransferase <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine
Registry number: EC 2.3.1.40
Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase
(26 Jun 1999)
acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source
Registry number: EC 2.3.1.129
Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein
(26 Jun 1999)
acyl carrier protein <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria.
(09 Oct 1997)
acyl carrier protein acylase <enzyme> From E coli
Registry number: EC 2.3.1.-
Synonym: acp acylase
(26 Jun 1999)
acyl protein synthetase <enzyme> Component of the fatty acid reductase complex of luminescent bacteria
Registry number: EC 2.3.1.-
Synonym: luxe gene product, fatty acyl-protein synthetase
(26 Jun 1999)
AKT1 protein kinase <enzyme> Human homolog of v-akt oncogene product
Registry number: EC 2.7.10.-
Synonym: akt1 protein, human
(26 Jun 1999)
AMP-activated protein kinase kinase <enzyme> An endogenous kinase kinase; reactivates the inactive form of AMP-activated protein kinase (AMP-pk); phosphorylates the 63-kD subunit of AMP-pk
Registry number: EC 2.7.1.-
Synonym: AMP-pk reactivator, hmg CoA reductase kinase kinase
(26 Jun 1999)
amyloid beta-protein A 4 kD protein, 39-43 amino acids long, expressed by a gene located on chromosome 21. It is the major protein subunit of the vascular and plaque amyloid filaments in individuals with alzheimer's disease and in aged individuals with trisomy 21 (down syndrome). The protein is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
(12 Dec 1998)
amyloid beta-protein precursor A precursor to the amyloid-beta protein (beta/a4). Alterations in the expression of the amyloid beta-protein precursor (abpp) gene, located on chromosome 21, plays a role in the development of the neuropathology common to both alzheimer disease and down syndrome. Abpp is associated with the extensive extracellular matrix secreted by neuronal cells. Upon cleavage, this precursor produces three proteins of varying amino acid lengths: 695, 751, and 770. The beta/a4 (695 amino acids) or beta-amyloid protein is the principal component of the extracellular amyloid in senile plaques found in alzheimer disease, down syndrome and, to a limited extent, in normal aging.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á